Tasigna And Atherosclerosis-Related Diseases: A Snapshot Of The Medical Literature From Back In April 2013

Despite Evidence That Tasigna Accelerates Atherosclerosis, Novartis Does Little To Warn Doctors And Patients In The US   (Posted by Tom Lamb at DrugInjuryWatch.com)   In a recent article, "Tasigna Side Effects Include Ischemic Cerebrovascular Events, Ischemic Heart Disease, And Peripheral Arterial Occlusive Disease", our primary focus was on the difference between Tasigna drug safety warnings provided by Novartis in Canada (more) as opposed to the US (less). For this article we take a closer look at what had been discussed in the medical literature about the atherosclerosis side effect associated with Tasigna (nilotinib) no later than April 2013. We are doing this review because it was during April 2013 that Novartis Pharmaceuticals Canada Inc. took these actions: Sent a so-called "Dear Doctor" letter in Canada (but not the US) by warning about some serious side effects associated with Tasigna; and, Issued a Tasigna drug label change in Canada (but…

Read more detail on Recent Health Care Law posts –

This entry was posted in Health Law and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply